Journal issues > Issue 5, September 2022 > Highlights in multiple myeloma

Highlights in multiple myeloma

By: J. Blokken PhD, PharmD, T. Feys MBA, MSc

SUMMARY

During the past European Hematology Association’s annual congress (EHA 2022), four oral sessions were devoted to clinical trials and recent advances in myeloma. These sessions covered newly diagnosed multiple myeloma (MM), antibody-based therapy in relapsed/refractory (RR) MM, BCMA-directed treatment in RRMM and biology and translational research. Below, we summarise the highlights from some of the studies that were presented in each of these sessions.

(BELG J HEMATOL 2022;13(5):219–23)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top